메뉴 건너뛰기




Volumn 8, Issue 3, 2007, Pages 121-131

Analysis of treatment costs for HIV RNA reductions and CD4 increases for darunavir versus other antiretrovirals in treatment-experienced, HIV-infected patients

Author keywords

Darunavir; Enfuvirtide; Health economics; Nucleoside analogues; Protease inhibitor

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EMITRICABINE; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NUCLEOSIDE DERIVATIVE; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

EID: 34547204078     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0803-121     Document Type: Article
Times cited : (5)

References (25)
  • 1
    • 33747122666 scopus 로고    scopus 로고
    • Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel
    • Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006,296:827-843.
    • (2006) JAMA , vol.296 , pp. 827-843
    • Hammer, S.M.1    Saag, M.S.2    Schechter, M.3
  • 2
    • 0035958773 scopus 로고    scopus 로고
    • Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults
    • Bartlett J, DeMasi R, Quinn J, Moxham C, Rousseau, F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS. 2001;15(11):1369-1377.
    • (2001) AIDS , vol.15 , Issue.11 , pp. 1369-1377
    • Bartlett, J.1    DeMasi, R.2    Quinn, J.3    Moxham, C.4    Rousseau, F.5
  • 3
    • 84858101786 scopus 로고    scopus 로고
    • US Department of Health and Human Services, Available at:, Accessed May
    • US Department of Health and Human Services. Darunavir prescribing information. Available at: www.aidsinfo.nih. gov. Accessed May 2007.
    • (2007) Darunavir prescribing information
  • 4
    • 19544386471 scopus 로고    scopus 로고
    • TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates
    • De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother. 2005;49:2314-2321.
    • (2005) Antimicrob Agents Chemother , vol.49 , pp. 2314-2321
    • De Meyer, S.1    Azijn, H.2    Surleraux, D.3
  • 5
    • 20644450806 scopus 로고    scopus 로고
    • TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: A 14-day proof of principle trial
    • Arasteh K, Clumeck N, Pozniak A, et al. TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof of principle trial. AIDS. 2005;19:943-947.
    • (2005) AIDS , vol.19 , pp. 943-947
    • Arasteh, K.1    Clumeck, N.2    Pozniak, A.3
  • 6
    • 34547186809 scopus 로고    scopus 로고
    • Katlama C, Berger D, Bellos N, et al. Efficacy of TMC114/r in 3-class experienced patients with limited treatment options: 24-week planned interim analysis of 2 96-week multinational dose-finding trials. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; February 2005; Boston, Massachusetts, USA. Abstract 164LB.
    • Katlama C, Berger D, Bellos N, et al. Efficacy of TMC114/r in 3-class experienced patients with limited treatment options: 24-week planned interim analysis of 2 96-week multinational dose-finding trials. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; February 2005; Boston, Massachusetts, USA. Abstract 164LB.
  • 7
    • 34547203224 scopus 로고    scopus 로고
    • Katlama C, Carvalho M, Cooper D, et al. POWER 1 (TMC-114-C213 Study) week 24 analysis. In: Program and abstracts of the Third IAS Conference on HIV Pathogenesis; July 2005; Rio de Janeiro, Brazil. Abstract WeOaLB0102.
    • Katlama C, Carvalho M, Cooper D, et al. POWER 1 (TMC-114-C213 Study) week 24 analysis. In: Program and abstracts of the Third IAS Conference on HIV Pathogenesis; July 2005; Rio de Janeiro, Brazil. Abstract WeOaLB0102.
  • 8
    • 34547181045 scopus 로고    scopus 로고
    • POWER 2 (TMC114-202 study). Week 24 Efficacy analysis
    • December, Washington, DC, USA. Abstract H-1094
    • Wilkin T, Haubrich R, Steinhart C, et al. POWER 2 (TMC114-202 study). Week 24 Efficacy analysis. In: Program and abstracts of ICAAC; December 2005; Washington, DC, USA. Abstract H-1094.
    • (2005) Program and abstracts of ICAAC
    • Wilkin, T.1    Haubrich, R.2    Steinhart, C.3
  • 10
    • 22444439664 scopus 로고    scopus 로고
    • Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures
    • Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005;19:685-694.
    • (2005) AIDS , vol.19 , pp. 685-694
    • Johnson, M.1    Grinsztejn, B.2    Rodriguez, C.3
  • 12
    • 29844453324 scopus 로고    scopus 로고
    • Tipranavir: A protease inhibitor for multi-drug resistant HIV-1
    • Best B, Haubrich R. Tipranavir: a protease inhibitor for multi-drug resistant HIV-1. Exper Opin Invest Drugs. 2006;15(1):59-70.
    • (2006) Exper Opin Invest Drugs , vol.15 , Issue.1 , pp. 59-70
    • Best, B.1    Haubrich, R.2
  • 14
    • 0038576281 scopus 로고    scopus 로고
    • Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America
    • Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2175-2185.
    • (2003) N Engl J Med , vol.348 , pp. 2175-2185
    • Lalezari, J.P.1    Henry, K.2    O'Hearn, M.3
  • 15
    • 0037849954 scopus 로고    scopus 로고
    • Efficacy of enfuvirtide in patients infected with drug-resistant human immunodeficiency virus type 1 in Europe and Australia
    • Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant human immunodeficiency virus type 1 in Europe and Australia. N Engl J Med. 2003;348:2186-2195.
    • (2003) N Engl J Med , vol.348 , pp. 2186-2195
    • Lazzarin, A.1    Clotet, B.2    Cooper, D.3
  • 16
    • 0141609130 scopus 로고    scopus 로고
    • Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: A randomized trial
    • Squires K, Pozniak AL, Pierone G, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med. 2003;139(5 pt 1):313-320.
    • (2003) Ann Intern Med , vol.139 , Issue.5 PART 1 , pp. 313-320
    • Squires, K.1    Pozniak, A.L.2    Pierone, G.3
  • 17
    • 0034069732 scopus 로고    scopus 로고
    • The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: Results from a randomised, double-blind trial
    • Katlama C, Clotet B, Plettenberg A, et al. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomised, double-blind trial. AIDS. 2000;14:781-789.
    • (2000) AIDS , vol.14 , pp. 781-789
    • Katlama, C.1    Clotet, B.2    Plettenberg, A.3
  • 18
    • 0030997937 scopus 로고    scopus 로고
    • Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial
    • CAESAR Coordinating Committee
    • CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet. 1997;349(9063):1413-1421.
    • (1997) Lancet , vol.349 , Issue.9063 , pp. 1413-1421
  • 19
    • 34547172889 scopus 로고    scopus 로고
    • Gebo K, Fleishman J, Conviser R, et al. Contemporary costs of HIV healthcare in the HAART era. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 2006; Denver, Colorado, USA. Abstract 537.
    • Gebo K, Fleishman J, Conviser R, et al. Contemporary costs of HIV healthcare in the HAART era. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 2006; Denver, Colorado, USA. Abstract 537.
  • 20
    • 33645058159 scopus 로고    scopus 로고
    • Distribution of health-care expenditures for HIV-infected patients
    • Chen R, Accortt, N, Westfall A, et al. Distribution of health-care expenditures for HIV-infected patients. Clin Infect Dis. 2006;42:1002-1010.
    • (2006) Clin Infect Dis , vol.42 , pp. 1002-1010
    • Chen, R.1    Accortt, N.2    Westfall, A.3
  • 21
    • 3042740596 scopus 로고    scopus 로고
    • Predictors of trend in CD4-positive T cell count and mortality among HIV-1 infected individuals with virological failure to all three antiretroviral-drug classes
    • Ledergerber B, Lundgren J, Walker A, et al. Predictors of trend in CD4-positive T cell count and mortality among HIV-1 infected individuals with virological failure to all three antiretroviral-drug classes. Lancet. 2004;364:51-62.
    • (2004) Lancet , vol.364 , pp. 51-62
    • Ledergerber, B.1    Lundgren, J.2    Walker, A.3
  • 22
    • 34547217640 scopus 로고    scopus 로고
    • Benzie A, Bansi L, Sabin C, Walsh J, Phillips A. Viral rebound in patients on HAART with viral suppression. Presented at the BHIVA Spring Conference; April 2006; Brighton, UK [abstract 09]. HIV Med. 2006;7(suppl 1):1-9.
    • Benzie A, Bansi L, Sabin C, Walsh J, Phillips A. Viral rebound in patients on HAART with viral suppression. Presented at the BHIVA Spring Conference; April 2006; Brighton, UK [abstract 09]. HIV Med. 2006;7(suppl 1):1-9.
  • 23
    • 34547228421 scopus 로고    scopus 로고
    • DeMasi R, Thommes J, Graham N. Currently marketed nucleosides provide only marginal additional viral load (VL) suppression to regimens including enfuvirtide (ENF) and boosted Pis (PI/r) in triple class experienced patients. In: Program and abstracts of the XVI International AIDS Conference; August 2006; Toronto, Canada. Abstract THPE0125.
    • DeMasi R, Thommes J, Graham N. Currently marketed nucleosides provide only marginal additional viral load (VL) suppression to regimens including enfuvirtide (ENF) and boosted Pis (PI/r) in triple class experienced patients. In: Program and abstracts of the XVI International AIDS Conference; August 2006; Toronto, Canada. Abstract THPE0125.
  • 24
    • 33748028822 scopus 로고    scopus 로고
    • Initial treatment of HIV infection: Randomized trials with clinical end points are still needed
    • Hughes MD. Initial treatment of HIV infection: randomized trials with clinical end points are still needed. J Infect Dis. 2006;194:542-544.
    • (2006) J Infect Dis , vol.194 , pp. 542-544
    • Hughes, M.D.1
  • 25
    • 33846490256 scopus 로고    scopus 로고
    • Cost to achieve an undetectable viral load using recommended antiretroviral regimens
    • Basu RP, Grimes RM, Helmy A. Cost to achieve an undetectable viral load using recommended antiretroviral regimens. HIV Clin Trials. 2006;7:309-318.
    • (2006) HIV Clin Trials , vol.7 , pp. 309-318
    • Basu, R.P.1    Grimes, R.M.2    Helmy, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.